PL339414A1 - Antagonistic vitronectin receptor - Google Patents

Antagonistic vitronectin receptor

Info

Publication number: PL339414A1
Authority: PL; Poland
Prior art keywords: antagonistic; vitronectin receptor; vitronectin; receptor; antagonistic vitronectin
Prior art date: 1997-09-24

Application number

PL98339414A

Other languages

English (en)

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-09-24

Filing date

1998-09-24

Publication date

2000-12-18

1998-09-24 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

2000-12-18 Publication of PL339414A1 publication Critical patent/PL339414A1/xx

Links

102100022337 Integrin alpha-V Human genes 0.000 title 1
108010048673 Vitronectin Receptors Proteins 0.000 title 1
230000003042 antagnostic effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PL98339414A 1997-09-24 1998-09-24 Antagonistic vitronectin receptor PL339414A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US5986797P	1997-09-24	1997-09-24

Publications (1)

Publication Number	Publication Date
PL339414A1 true PL339414A1 (en)	2000-12-18

Family

ID=22025805

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL98339414A PL339414A1 (en)	1997-09-24	1998-09-24	Antagonistic vitronectin receptor

Country Status (13)

Country	Link
EP (1)	EP1023073A1 (fr)
JP (1)	JP2002500162A (fr)
KR (1)	KR20010024249A (fr)
CN (1)	CN1271284A (fr)
AU (1)	AU9578798A (fr)
BR (1)	BR9813214A (fr)
CA (1)	CA2304000A1 (fr)
HU (1)	HUP0003931A2 (fr)
IL (1)	IL135188A0 (fr)
NO (1)	NO20001515L (fr)
PL (1)	PL339414A1 (fr)
TR (1)	TR200000786T2 (fr)
WO (1)	WO1999015178A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1150965A4 (fr)	1999-02-03	2002-05-15	Merck & Co Inc	Derives de la benzazepine utilises comme antagonistes du recepteur alpha-v de l'integrine
US6514964B1 (en)	1999-09-27	2003-02-04	Amgen Inc.	Fused cycloheptane and fused azacycloheptane compounds and their methods of use
ES2366775T3 (es)	2001-04-24	2011-10-25	Merck Patent Gmbh	POLITERAPIA UTILIZANDO AGENTES ANTIANGIOGÉNICOS Y TNF(alfa).
WO2003059251A2 (fr)	2001-10-22	2003-07-24	The Scripps Research Institute	Composes de ciblage d'anticorps
US7368566B2 (en)	2003-04-04	2008-05-06	Smithkline Beecham Corporation	Process and intermediates for preparing benzazepines
WO2005075655A2 (fr)	2004-02-02	2005-08-18	Pioneer Hi-Bred International, Inc.	Facteur de transcription odp2 (ovule development protein 2) du domaine ap2 et procedes pour l'utiliser
UA87854C2 (en)	2004-06-07	2009-08-25	Мерк Энд Ко., Инк.	N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
AU2007207465B2 (en)	2006-01-18	2012-12-06	Merck Patent Gmbh	Specific therapy using integrin ligands for treating cancer
BRPI0806596A2 (pt)	2007-01-18	2013-07-23	Merck Patent Ges Mit Berchraenkter Haftung	medicamento e terapia especÍfica usando-se ligantes de integrina para o tratamento de cÂncer
AU2008321770B2 (en)	2007-11-16	2012-09-06	Ube Industries, Ltd.	Benzazepinone compound
US8076475B2 (en) *	2008-03-06	2011-12-13	Glaxosmithkline Llc	Process
WO2010093706A2 (fr)	2009-02-10	2010-08-19	The Scripps Research Institute	Vaccination programmée chimiquement
WO2010113958A1 (fr)	2009-03-30	2010-10-07	宇部興産株式会社	Composition pharmaceutique pour la prévention ou le traitement de maladies ophtalmiques
EP2445534A2 (fr)	2009-05-25	2012-05-02	Merck Patent GmbH	Administration continue du cilengitide dans des traitements du cancer
WO2011082318A2 (fr)	2009-12-30	2011-07-07	Pioneer Hi-Bred International, Inc.	Procédés et compositions pour l'introduction et l'expression régulée de gènes dans des plantes
US8704041B2 (en)	2009-12-30	2014-04-22	Pioneer Hi Bred International Inc	Methods and compositions for targeted polynucleotide modification
ES2864079T3 (es)	2014-05-30	2021-10-13	Pfizer	Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
WO2023275715A1 (fr)	2021-06-30	2023-01-05	Pfizer Inc.	Métabolites de modulateurs sélectifs du récepteur des androgènes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA60311C2 (uk) *	1996-10-02	2003-10-15	Смітклайн Бічам Корпорейшн	Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція

1998
- 1998-09-24 WO PCT/US1998/019987 patent/WO1999015178A1/fr not_active Ceased
- 1998-09-24 TR TR2000/00786T patent/TR200000786T2/xx unknown
- 1998-09-24 CA CA002304000A patent/CA2304000A1/fr not_active Abandoned
- 1998-09-24 BR BR9813214-8A patent/BR9813214A/pt not_active Application Discontinuation
- 1998-09-24 CN CN98809494A patent/CN1271284A/zh active Pending
- 1998-09-24 KR KR1020007003093A patent/KR20010024249A/ko not_active Withdrawn
- 1998-09-24 JP JP2000512547A patent/JP2002500162A/ja not_active Withdrawn
- 1998-09-24 PL PL98339414A patent/PL339414A1/xx unknown
- 1998-09-24 HU HU0003931A patent/HUP0003931A2/hu unknown
- 1998-09-24 AU AU95787/98A patent/AU9578798A/en not_active Abandoned
- 1998-09-24 IL IL13518898A patent/IL135188A0/xx unknown
- 1998-09-24 EP EP98949471A patent/EP1023073A1/fr active Pending
2000
- 2000-03-23 NO NO20001515A patent/NO20001515L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU9578798A (en)	1999-04-12
BR9813214A (pt)	2000-08-29
JP2002500162A (ja)	2002-01-08
TR200000786T2 (tr)	2000-08-21
EP1023073A1 (fr)	2000-08-02
CN1271284A (zh)	2000-10-25
WO1999015178A1 (fr)	1999-04-01
NO20001515D0 (no)	2000-03-23
NO20001515L (no)	2000-03-23
IL135188A0 (en)	2001-05-20
CA2304000A1 (fr)	1999-04-01
KR20010024249A (ko)	2001-03-26
HUP0003931A2 (hu)	2001-10-28

Publication	Publication Date	Title
PL332674A1 (en)	1999-09-27	Antagonistic receptor of vitronectin
EP1000031A4 (fr)	2001-08-16	Antagonistes du recepteur de vitronectine
ZA9896B (en)	1998-10-14	Vitronectin receptor antagonists
EP0767792A4 (fr)	2002-11-20	Antagonistes du recepteur de la vitronectine
ZA955391B (en)	1996-02-09	Vitronectin receptor antagonists
EP1007051A4 (fr)	2001-08-29	Antagonistes du recepteur de l'integrine
PL339413A1 (en)	2000-12-18	Antagonistic vitronectin receptor
IL135028A0 (en)	2001-05-20	Vitronectin receptor antagonists
IL135188A0 (en)	2001-05-20	Vitronectin receptor antagonist
IL138245A0 (en)	2001-10-31	Vitronectin receptor antagonists
EP1027337A4 (fr)	2002-04-03	Antagonistes des recepteurs d'integrines
EG24025A (en)	2008-03-26	Vitronectin receptor antagonist
PL346157A1 (en)	2002-01-28	Vitronectin receptor antagonists
ZA988562B (en)	1999-03-19	Vitronectin receptor antagonists
HK1026694A (en)	2000-12-22	Vitronectin receptor antagonists
HK1031115A (en)	2001-06-01	Vitronectin receptor antagonists
SI0957917T1 (sl)	2006-04-30	Antagonisti receptorja vitronektina
GB9822331D0 (en)	1998-12-09	Vitronectin receptor antagonists
GB9810882D0 (en)	1998-07-22	Vitronectin receptor antagonists
GB9812686D0 (en)	1998-08-12	Vitronectin receptor antagonists
GB9811295D0 (en)	1998-07-22	Vitronectin receptor antagonists
GB9810182D0 (en)	1998-07-08	Vitronectin receptor antagonists
GB9807384D0 (en)	1998-06-03	Vitronectin receptor antagonists
GB9807382D0 (en)	1998-06-03	Vitronectin receptor antagonists
GB9815803D0 (en)	1998-09-16	Vitronectin receptor antagonists